Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Applications & Clinical Translation of Tissue Engineering

Sharon Presnell's Biography

Sharon Presnell, Executive Vice President, R&D , Organovo, Inc.

Sharon Collins Presnell, PhD, Chief Technology Officer and Executive Vice President of Research & Development, has more than 16 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of cell-based tools and reagents for BD's life sciences portfolio. At BD, she grew and led a large multi-disciplinary team to build and validate screening platforms for cell growth, differentiation, and characterization and secured revenue-generating commercial partnerships with pharma partners. Sharon joined Tengion, Inc. in 2007, and as the Senior Vice President of Regenerative Medicine Research, was responsible for leading the discovery and early development of Tengion’s Neo-Kidney Augment™, a cell-based therapy now in clinical trials for patients with chronic kidney disease. As the Chief Technology Officer at Organovo, Dr. Presnell has led the growth and development of the R&D organization, including evolution of the company’s technology portfolio, and has played an instrumental role in securing funds in support of corporate growth initiatives. Sharon holds a PhD in pathology from the Medical College of Virginia.

Sharon Presnell Image

Applications Development with 3D Human Tissues created via Additive Manufacturing Approaches

Monday, 9 February 2015 at 17:00

Add to Calendar ▼2015-02-09 17:00:002015-02-09 18:00:00Europe/LondonApplications Development with 3D Human Tissues created via Additive Manufacturing

Additive manufacturing is emerging as a compelling means to generate three-dimensional structures comprising living cells for use in in vitro and in vivo applications, with an exceptional degree of architectural control. The value of tissues produced using these methodologies will be determined, ultimately, by their functional performance in in vitro and in vivo applications. Phenotypic and functional attributes of 3D-bioprinted human tissues, such as liver, will be discussed.

Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonClinical Applications and Clinical Translation of Tissue